Blinatumomab for the treatment of B-cell lymphoma

Bibliography

• Howlader N, Noone AM, Krapcho M, et al. eidtors SEER cancer statistics review, 1975-2011. National Cancer Institute, Bethesda (MD); 2014
   Google Scholar
• Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-57
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-14
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Al Ali NH, Beg MS, et al. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk 2011;11:257-60
   PubMed Web of Science ®Google Scholar
• Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev 2012;26:279-88
   PubMed Web of Science ®Google Scholar
• Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829-36
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998;16:3264-9
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJM, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013;87:146-71
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120:1175-84
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23
   PubMed Web of Science ®Google Scholar
• Wilson WH, Gerecitano JF, Goy A, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 Study. ASH Annu Meet Abstr 2012;120:686
   Google Scholar
• Mohamed AJ, Yu L, Bäckesjö C-M, et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009;228:58-73
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42
   PubMed Web of Science ®Google Scholar
• Bartlett NL, LaPlant BR, Qi J, et al. Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial. ASH Annu Meet Abstr 2014;124:abstract 800
   Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014;123:3406-13
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-7
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-8
   PubMed Web of Science ®Google Scholar
• Seymour JF, Davids MS, Pagel JM, et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 2013;122:872
   PubMed Web of Science ®Google Scholar
• Davids MS, Seymour JF, Gerecitano JF, et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood 2013;122:1789
   PubMedGoogle Scholar
• Roberts AW, Ma S, Brander D, et al. Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). ASH Annu Meet Abstr 2014;124:abstract 325
   Google Scholar
• De Vos S, Flowers CR, Wang D, et al. The BCL-2 inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin’s lymphoma. ASH Annu Meet Abstr 2014;124:abstract 1722
   Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36
   PubMed Web of Science ®Google Scholar
• Merli M, Ferrario A, Basilico C, et al. Novel agents in indolent lymphomas. Ther Adv Hematol 2013;4:133-48
   PubMedGoogle Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31:3688-95
   PubMed Web of Science ®Google Scholar
• Martin P, Jung S-H, Johnson JL, et al. CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol 2014;32(Suppl):abstract 8521
   Google Scholar
• Leonard JP, Jung S-H, Johnson JL, et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012;30(Suppl):abstract 8000
   Google Scholar
• Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013;10:267-76
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014;32
   Google Scholar
• Kochenderfer JN, Somerville R, Lu L, et al. Anti-CD19 cAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. ASH Annu Meet Abstr 2014;124:abstract 550
   Google Scholar
• Bryan LJ, Gordon LI. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev 2014
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell S, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. ASH Annu Meet Abstr 2014;124:abstract 291
   Google Scholar
• Morschhauser F, Flinn I, Advani RH, et al. Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-hodgkin lymphoma. ASH Annu Meet Abstr 2014;124:abstract 4457
   Google Scholar
• Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res 2003;9:4296-303
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96
   PubMed Web of Science ®Google Scholar
• Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012;12:12
   PubMedGoogle Scholar
• Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005;10:1237-44
   PubMed Web of Science ®Google Scholar
• Löffler A, Kufer P, Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-103
   PubMed Web of Science ®Google Scholar
• Baracho GV, Miletic AV, Omori SA, et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011;23:178-83
   PubMed Web of Science ®Google Scholar
• Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013;17:385-92
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2014;16:57-66
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory b-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32:4134-40
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M, Noppeney R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. ASH Annu Meet Abstr 2011;118:1637
   Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective. Pharmacol Ther 2012;136:334-42
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M, Hess G, et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE®) antibody construct blinatumomab: primary analysis results from an open-label, phase 2 study. ASH Annu Meet Abstr 2014;124:abstract 4460
   Google Scholar
• Traunecker A, Lanzavecchia A, Karjalainen K. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J 1991;10:3655-9
   PubMed Web of Science ®Google Scholar
• Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-71
   PubMed Web of Science ®Google Scholar
• Brischwein K, Parr L, Pflanz S, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807
   PubMed Web of Science ®Google Scholar
• Dreier T, Baeuerle PA, Fichtner I, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003;170:4397-402
   PubMed Web of Science ®Google Scholar
• Brandl C, Haas C, d’Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-63
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011;317:1255-60
   PubMed Web of Science ®Google Scholar
• Gruen M, Bommert K, Bargou RC. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 2004;53:625-32
   PubMed Web of Science ®Google Scholar
• Renner C, Held G, Ohnesorge S, et al. Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Immunobiology 1997;197:122-32
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104
   PubMed Web of Science ®Google Scholar
• d’Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465-73
   PubMed Web of Science ®Google Scholar
• Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 2013;98:1930-8
   PubMed Web of Science ®Google Scholar
• Romano MF, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92:990-5
   PubMed Web of Science ®Google Scholar
• D’amico A, Borleri G, Finazzi MC, et al. Massive, clinical grade expansion of polyclonal T cells using blinatumomab for adoptive autologous cellular therapy of CLL patients. Blood 2013;122:3272
   Google Scholar
• Wu B, Hijazi Y, Wolf A, et al. Pharmacokinetics (PK) of blinatumomab and its clinical implications. ASCO Meet Abstr 2013;31:3048
   Google Scholar
• Hijazi Y, Klinger M, Schub A, et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). ASCO Meet Abstr 2013;31:3051
   Google Scholar
• Viardot A, Goebeler M, Scheele JS, et al. Treatment of patients with non-hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 {micro}g/m2/d is tolerable and highly effective. ASH Annu Meet Abstr 2010;116:2880
   Google Scholar
• Goebeler M, Pfreundschuh M, Adrian N, et al. Open-label phase 2 study of the bispecific T-Cell engager (BiTE®) blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 2013;122:1811
   Google Scholar